1Sten- Linder M, Linder C, Strander H,et al. Angiostatin fragments in urine from patients with malignant disease [J]. AnticancerRes, 1999, 19(4C):3409-3414.
2Cao Y, Veitonmaki N, Keough K, et al. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients[J],Int J Mol Med, 2000, 5(5) :547-551.
3Kostner K, Spitzauer S,Rumpold H, et al. Urinary excretion of apolipoprotein(a) : relation to other plasma proteins [J]. ClinChimActa, 2001, 304(1 -2):29-37.
4Jeon SH, Lee SJ, Chang SG. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors [ J ]. Oncol Rep, 2001, 8 (6) : 1265-1267.
5Eisen T, Boshoff C, MakI, et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [ J]. Br J Cancer, 2000, 82(4) :812-817.
6Fujiwaki R, Hata K, Iida K, et al. Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis[ J]. Anticancer Res, 2000, 20(2B) :1317-1322.
7Sivridis E. Angiogenesis and endometrial cancer[ J]. Anticancer Res, 2001, 21(6B) :4383-4388.
8Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer [ J ]. nol Pathol, 2002, 55 (6) :348-359.
9Abulafia O, Sherer DM. Angiogenesis of the ovary. Am J Obstet Gynecol, 2000, 182( 1 Pt 1 ) :240-246.
